Improving liquidity and strategic activity are supporting a more resilient medtech investment environment. Capital is increasingly concentrating around differentiated technologies, scalable platforms, and proven growth pathways. Following a record funding...

Defense technology is rapidly evolving into a mainstream venture investment category with expanding investor interest. Record funding, broader adoption, and emerging exit pathways are strengthening market maturity. Defense innovation is...

Cybersecurity funding remains resilient, but the VC market is becoming selective. As AI reshapes enterprise security requirements and risk management priorities, investors are concentrating capital in a smaller group of...

Consumer AI has scaled rapidly, but revenue generation remains limited and concentrated among a few platforms. The next phase will be defined by monetization, distribution control, cost efficiency, and sustainable...

US venture capital (VC) is stabilizing in 2026 as early-stage momentum, selective late-stage activity, and improving liquidity reset the market. AI continues to dominate investment priorities, driving opportunity and sharper...

Public investors are rewarding profitability, sector alignment, and valuation discipline, not just top-line growth. The IPO window remains narrow, demanding stronger fundamentals and clearer exit strategies. After years of volatility,...

Valuations are resetting across US venture markets as down rounds normalize, exits remain constrained, and capital concentrates in a few dominant sectors. For investors, this is both a moment of...

Biopharma venture capital (VC) dealmaking slowed sharply in 2Q25, with investment consolidating into select, larger transactions targeting lower-risk opportunities. Investors are prioritizing clinically validated assets, AI-enabled R&D models, and M&A-driven...

AI and ML VC (venture capital) investment reached record highs in 1Q25, driven by the scale of infrastructure and the breadth of applications. Yet capital remains unevenly distributed, forcing investors...

Venture and private equity (PE) activity in medtech is rebounding after a multi-year lull, led by platform-driven innovation and disciplined capital deployment. Yet regulatory ambiguity and muted exit markets demand...